Matt Gline, Roivant CEO (Credit: Roivant)

Roivant an­nounces study win in eye dis­ease for Pfiz­er as­set, plans $1.5B share buy­back

Roivant has found a use for its ex­tra cash, and is re­veal­ing the lat­est da­ta from the big phar­ma re­la­tion­ship that helped gen­er­ate those funds …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.